Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HelixBind has developed a proprietary molecular diagnostic platform—RaPID/BSI—that enables rapid, species-level identification of over twenty pathogens directly from whole blood within a few hours. This approach bypasses traditional blood culture methods that take days and can identify ongoing infections even in patients already receiving antimicrobials. Peer-reviewed studies have demonstrated high accuracy and low false positive rates compared to sequencing-based assays. The company’s technology aims to improve sepsis management by enabling earlier targeted antimicrobial therapy and better stewardship.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HelixBind.